• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Baxter to Host Annual Meeting of Stockholders in Virtual Format

    3/26/25 9:00:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care
    Get the next $BAX alert in real time by email

    Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2025 Annual Meeting) in a virtual format on Tuesday, May 6, 2025 at 9 a.m., Central Time, as disclosed in Baxter's proxy statement for the 2025 Annual Meeting. Online access to the 2025 Annual Meeting will begin at 8:45 a.m., Central Time. Stockholders will not be able to attend the 2025 Annual Meeting in person. The virtual format provides a safe, convenient and cost-effective experience to all stockholders regardless of location.

    As always, whether or not a stockholder plans to attend the virtual 2025 Annual Meeting, all stockholders of record are encouraged to vote their shares prior to the 2025 Annual Meeting by one of the methods described in the proxy materials for the 2025 Annual Meeting.

    Attending the 2025 Annual Meeting

    Stockholders of record may attend the 2025 Annual Meeting by accessing www.virtualshareholdermeeting.com/BAX2025 and entering their 16-digit control number on their proxy card or notice of availability of proxy materials. Stockholders that hold shares in "street name" (i.e., through an account at a broker or other nominee), should follow their broker's or nominee's instructions to obtain their 16-digit control number or otherwise attend through the broker or nominee. A list of Baxter's stockholders of record will be available for examination by stockholders on the 2025 Annual Meeting website during the meeting.

    Asking Questions

    Stockholders of record may submit questions in two ways. Stockholders may ask a question before the 2025 Annual Meeting, beginning on April 22, 2025 and until 11:59 p.m., Central Time, on May 5, 2025, by logging into www.proxyvote.com and entering their 16-digit control number. Once past the login screen, stockholders should click on "Question for Management," type in a question and click "Submit." Alternatively, stockholders of record will be able to submit questions live during the 2025 Annual Meeting by accessing www.virtualshareholdermeeting.com/BAX2025, typing a question into the "Ask a Question" field and clicking "Submit." Only questions pertinent to 2025 Annual Meeting matters will be answered during the meeting, subject to time constraints. If any questions pertinent to 2025 Annual Meeting matters cannot be answered during the meeting due to time constraints, Baxter will post and answer a representative set of these questions online at https://investor.baxter.com. The questions and answers will be available as soon as reasonably practicable after the 2025 Annual Meeting and will remain available until one week after posting.

    Voting Shares

    Stockholders may vote their shares prior to the 2025 Annual Meeting using one of the methods described in the proxy materials for the 2025 Annual Meeting.

    Stockholders that have not voted their shares prior to the 2025 Annual Meeting will be able to vote their shares electronically at the 2025 Annual Meeting by clicking "Vote Here" on the meeting website. If a stockholder has already voted their shares prior to the 2025 Annual Meeting, they do not need to vote again.

    Attending the 2025 Annual Meeting as a Guest

    Anyone who would like to attend the 2025 Annual Meeting as a guest in listen-only mode can do so by accessing the Meeting at www.virtualshareholdermeeting.com/BAX2025 and by entering the information requested on the screen. Please note guests will not have the ability to ask questions or vote during the 2025 Annual Meeting.

    About Baxter

    Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company's rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on X, LinkedIn and Facebook.

    Baxter is a registered trademark of Baxter International Inc.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250325481994/en/

    Media Contact

    Stacey Eisen, (224) 948-5353

    [email protected]

    Investor Contact

    Clare Trachtman, (224) 948-3020

    Get the next $BAX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BAX

    DatePrice TargetRatingAnalyst
    2/26/2025$42.00Buy
    Goldman
    2/24/2025Hold → Buy
    Argus
    2/20/2025$39.00Overweight
    Barclays
    7/15/2024$39.00 → $30.00Equal-Weight → Underweight
    Morgan Stanley
    5/30/2024$36.00Neutral
    Goldman
    5/10/2024$40.00Buy → Hold
    TD Cowen
    5/30/2023$45.00Equal-Weight
    Morgan Stanley
    3/29/2023$43.00Neutral
    UBS
    More analyst ratings

    $BAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Wilkes David S. was granted 7,183 shares, increasing direct ownership by 43% to 23,906 units (SEC Form 4)

      4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

      5/8/25 4:29:28 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Director Wendell Amy Mcbride was granted 7,183 shares, increasing direct ownership by 30% to 31,222 units (SEC Form 4)

      4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

      5/8/25 4:28:59 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Director Smith Cathy R was granted 7,183 shares, increasing direct ownership by 31% to 30,345 units (SEC Form 4)

      4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

      5/8/25 4:28:20 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care

    $BAX
    Financials

    Live finance-specific insights

    See more
    • Baxter Declares Quarterly Dividend

      Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on July 1, 2025, to stockholders of record as of May 30, 2025. The indicated annual dividend rate is $0.68 per share of common stock. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been operating at the critical intersection where innovat

      5/6/25 4:15:00 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Baxter Reports First-Quarter 2025 Results

      First-quarter sales from continuing operations of $2.63 billion increased 5% on both a reported and operational basis, exceeding the company's previously issued guidance1,2 First-quarter U.S. GAAP3 diluted earnings per share (EPS) from continuing operations of $0.13; adjusted diluted EPS from continuing operations of $0.55, exceeding the company's previously issued guidance Baxter increases bottom end of previous range for full-year 2025 adjusted diluted EPS guidance and now expects adjusted diluted EPS of $2.47 to $2.551 Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2025. "Our solid performance in the first quarter of

      5/1/25 7:15:00 AM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Baxter to Host First-Quarter 2025 Financial Results Conference Call for Investors

      Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its first-quarter 2025 financial results on Thursday, May 1, 2025 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I763359 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on B

      4/15/25 4:15:00 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care

    $BAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Baxter International Inc.

      SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

      11/13/24 1:08:27 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Baxter International Inc. (Amendment)

      SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

      2/13/24 5:00:53 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Baxter International Inc.

      SC 13G - BAXTER INTERNATIONAL INC (0000010456) (Subject)

      2/13/24 1:08:57 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care

    $BAX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Baxter Declares Quarterly Dividend

      Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on July 1, 2025, to stockholders of record as of May 30, 2025. The indicated annual dividend rate is $0.68 per share of common stock. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been operating at the critical intersection where innovat

      5/6/25 4:15:00 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Baxter Reports First-Quarter 2025 Results

      First-quarter sales from continuing operations of $2.63 billion increased 5% on both a reported and operational basis, exceeding the company's previously issued guidance1,2 First-quarter U.S. GAAP3 diluted earnings per share (EPS) from continuing operations of $0.13; adjusted diluted EPS from continuing operations of $0.55, exceeding the company's previously issued guidance Baxter increases bottom end of previous range for full-year 2025 adjusted diluted EPS guidance and now expects adjusted diluted EPS of $2.47 to $2.551 Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2025. "Our solid performance in the first quarter of

      5/1/25 7:15:00 AM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Baxter to Present at Bank of America Securities 2025 Health Care Conference

      Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Bank of America Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Joel Grade, Baxter's chief financial officer, is scheduled to present at 8:40 a.m. Pacific Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Sunday, November 9, 2025. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years

      4/29/25 4:15:00 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care

    $BAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman resumed coverage on Baxter with a new price target

      Goldman resumed coverage of Baxter with a rating of Buy and set a new price target of $42.00

      2/26/25 7:01:30 AM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Baxter upgraded by Argus

      Argus upgraded Baxter from Hold to Buy

      2/24/25 10:10:46 AM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Barclays resumed coverage on Baxter with a new price target

      Barclays resumed coverage of Baxter with a rating of Overweight and set a new price target of $39.00

      2/20/25 8:18:14 AM ET
      $BAX
      Medical/Dental Instruments
      Health Care

    $BAX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • October 18, 2024 - FDA Roundup: October 18, 2024

      For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

      10/18/24 4:16:25 PM ET
      $NVCR
      $BAX
      Medical/Dental Instruments
      Health Care

    $BAX
    SEC Filings

    See more
    • Baxter International Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

      5/8/25 4:15:37 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Baxter International Inc.

      10-Q - BAXTER INTERNATIONAL INC (0000010456) (Filer)

      5/6/25 4:34:41 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Baxter International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

      5/1/25 7:17:51 AM ET
      $BAX
      Medical/Dental Instruments
      Health Care

    $BAX
    Leadership Updates

    Live Leadership Updates

    See more
    • PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

      3/11/25 7:05:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of

      3/11/25 7:00:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Baxter Appoints Jeffrey A. Craig to Its Board

      Addition of Mr. Craig complements current board expertise with deep financial, broad operational and public company board experience Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed Jeffrey (Jay) A. Craig, former executive chair and chief executive officer (CEO) of Meritor Corporation, to its board of directors. Mr. Craig will serve on Baxter's Audit Committee. His appointment is effective today and brings the total number of directors serving the company to 12. "We are excited to welcome Jay to Baxter's board," said José (Joe) E. Almeida, chair, president and CEO. "As a former CEO, CFO, COO and public company auditor, Jay's broad-based busin

      9/9/24 9:00:00 AM ET
      $BAX
      Medical/Dental Instruments
      Health Care